The Biomedical Research and Innovation Institute of Cádiz (INiBICA) has reached its tenth anniversary since its establishment, becoming one of the leading health research structures in Andalucía and a national reference in clinical innovation. The center has succeeded in bridging the gap between laboratories and medical consultations, transforming healthcare in the province.
To mark its anniversary, the acting Minister of Health, Presidency, and Emergencies for the Regional Government of Andalucía, Antonio Sanz, visited the facilities to highlight the institution's evolution. According to Sanz, the institute has managed to translate scientific research into tangible improvements for the health of the province's citizens.
INiBICA's model relies on an extensive collaboration network connecting five hospitals and four university campuses. This structure facilitates the link between research and daily clinical practice, speeding up the delivery of scientific advancements to patients.
The institute's consolidation has been significantly strengthened in recent years, particularly between 2019 and 2021, with the establishment of stable research structures, the recruitment of specialized personnel, and enhanced coordination among the Regional Government of Andalucía, the Andalusian Health Service, and the University of Cádiz. Subsequently, the center focused on strengthening its scientific groups and adapting to national excellence standards, culminating in official accreditation by the Carlos III Health Institute in 2025.
The growth is particularly evident in the field of clinical trials. INiBICA currently conducts studies on innovative treatments and has achieved prominent international positions in recruiting participants for various trials.
Among the most significant cases is the PROTEUS study on prostate cancer, which recruited over 140 patients, placing the center among the leading participants worldwide. Furthermore, the Puerta del Mar University Hospital leads global recruitment for a trial aimed at premature newborns at risk of developing bronchopulmonary dysplasia.
Research activity has also driven academic and independent clinical trials focused on health issues particularly relevant to the region. In Jerez, between 2020 and 2025, clinical activity saw a 260% cumulative increase, reaching 149 active trials and 249 recruited patients.
INiBICA's impact extends beyond research, with knowledge generated from its projects now forming part of routine healthcare practice. New care models have been incorporated, such as virtual consultations for cardiovascular patient monitoring, the implementation of technologies like deep brain stimulation, more humanized care protocols, and artificial intelligence and mathematical medicine tools for disease diagnosis and prognosis.
The institute's expansion has also yielded economic and social benefits, including the creation of skilled jobs in research and management, the attraction of competitive national and international funding, and the establishment of new scientific infrastructures, all contributing to reducing territorial disparities in access to healthcare innovation within the province.
